Shares in IMCD NV jumped more than 5% on Tuesday after UBS Global Research upgraded the Netherlands-based specialty chemical distributor to "buy" from "neutral" and raised its price target to €100 from €85. UBS pointed to a "viable path back to 6-7% organic EPS growth," citing renewed inflationary pressure in oil and chemical markets and ongoing supply-chain constraints that could counteract prior deflationary pressures in the sector.
IMCD closed at €86.20 on July 13, marking a decline of about 25% over the past 12 months and sitting roughly 60% below its 2021 peak. UBS characterized this derating as the market pricing in three years of profit headwinds that followed a period of exceptional expansion in chemical distribution.
Since the onset of the Middle East conflict, UBS said it has observed rising oil and chemical price inflation. The bank expects these dynamics to prompt significant price increases from many of IMCD's suppliers and to sustain supply-chain stress, which together should provide a boost to growth. UBS quantified that effect as roughly a 2% uplift to growth in fiscal years 2026-27, noting this is smaller than the high-single-digit GP/unit tailwind the firm estimates IMCD benefited from in 2020-22.
UBS described its outlook for volumes as conservatively paced, projecting only a very gradual volume recovery in fiscal 2026. Nonetheless, the broker expects that this slow improvement will be sufficient to inflect top-line growth by the second quarter of 2026. IMCD is due to report results on July 29, and UBS's timing implies the broker anticipates the company will demonstrate that early recovery in those figures.
The upgrade and higher price target reflect UBS's financial revisions. The bank said it implemented 10-15% earnings-per-share upgrades and increased its discounted-cash-flow terminal margin assumption to 37% from 36%. On UBS's valuation metrics, IMCD now trades at roughly 11 times its 2027 estimated EV/EBITA, compared with about 13 times at the bank's €100 price target.
UBS reiterated IMCD's status as the market leader in specialty chemical distribution, pointing to a roughly 15% EBITA compound annual growth rate from 2015 to 2025. The broker outlined a path for a return to organic EPS growth above 6%, and said that growth could reach double digits if the company continues to expand through mergers and acquisitions, which UBS expects given the fragmentation of many markets IMCD serves.
To frame upside and downside outcomes, UBS provided scenario valuations. Its upside "compounding leader" case places a value of €140 per share, driven by faster volume recovery and sustained higher margins. Conversely, a downside "demand destruction" scenario, reflecting prolonged volume disruption, values the shares at €50. UBS also noted that IMCD currently trades at about a 15% discount to sector quality growth peers, a reversal from a 10-year average in which the company commanded roughly a 25% premium.
UBS highlighted several key risks to its thesis. A cyclical slowdown could weigh on demand, particularly in the roughly 45% of IMCD's end markets that are industrial. Regulatory and health-and-safety risks are intrinsic to chemical distribution, and the loss of key suppliers or customers could materially affect results. Additionally, fluctuations in product costs could negatively impact cost of goods sold, working capital or leverage if those cost increases cannot be passed on to customers.
Contextual note - UBS's guidance and scenarios rest on observable inflationary trends in oil and chemical prices and the broker's estimates for volume recovery and supplier pricing actions. The bank's revisions to EPS and terminal margin underpin its more constructive rating, while its scenario analysis underscores that outcomes remain sensitive to demand, pricing pass-through and operational risks.